Stephan K. Metzelder

We don’t have enough information about this author to calculate their statistics. If you think this is an error let us know.
Learn More
Gain-of-function mutations in the RAS and FLT3 genes are frequently found in cells of acute myeloid leukemia (AML), leading to constitutive activation of signaling pathways that regulate fundamental cellular processes, and are therefore attractive targets for AML therapy. The multi-targeted kinase inhibitor sorafenib is efficacious in AML with FLT3-internal(More)
  • 1